Fonte: Clinical rheumatology. Unidade: FM
Assuntos: LÚPUS ERITEMATOSO SISTÊMICO, PROTEÍNAS PROTO-ONCOGÊNICAS, PROTEÍNAS QUINASES, RECEPTORES IMUNOLÓGICOS, ARTRITE REUMATOIDE JUVENIL, NEFRITE, ANTICORPOS
ABNT
LIPHAUS, Bernadete L et al. Increased sMer, but not sAxl, sTyro3, and Gas6 relate with active disease in juvenile systemic lupus erythematosus. Clinical rheumatology, v. 39, n. 2, p. 509-514, 2020Tradução . . Disponível em: https://doi.org/10.1007/s10067-019-04799-5. Acesso em: 12 set. 2024.APA
Liphaus, B. L., Lima, L., Palmeira, P., Silva, C. A., Schainberg, C. G., & Sampaio, M. M. S. C. (2020). Increased sMer, but not sAxl, sTyro3, and Gas6 relate with active disease in juvenile systemic lupus erythematosus. Clinical rheumatology, 39( 2), 509-514. doi:10.1007/s10067-019-04799-5NLM
Liphaus BL, Lima L, Palmeira P, Silva CA, Schainberg CG, Sampaio MMSC. Increased sMer, but not sAxl, sTyro3, and Gas6 relate with active disease in juvenile systemic lupus erythematosus [Internet]. Clinical rheumatology. 2020 ; 39( 2): 509-514.[citado 2024 set. 12 ] Available from: https://doi.org/10.1007/s10067-019-04799-5Vancouver
Liphaus BL, Lima L, Palmeira P, Silva CA, Schainberg CG, Sampaio MMSC. Increased sMer, but not sAxl, sTyro3, and Gas6 relate with active disease in juvenile systemic lupus erythematosus [Internet]. Clinical rheumatology. 2020 ; 39( 2): 509-514.[citado 2024 set. 12 ] Available from: https://doi.org/10.1007/s10067-019-04799-5